The American College of Radiology Imaging Network (ACRIN) and the Gynecologic Oncology Group (GOG) have begun a study to evaluate two imaging modalities for identifying pelvic and abdominal lymph node metastases in patients with locoregionally advanced cervical cancer.
The trial will examine the role of PET/CT with FDG and MRI with the Combidex contrast agent from AMAG Pharmaceuticals of Cambridge, MA, according to the organizations. Approximately 10 ACRIN-approved sites will collaborate with a GOG member institution to reach 325 participants within three years; all participants will undergo lymph node sampling to determine the accuracy of the imaging exams.
Dr. Mostafa Atri of the University Health Network/Mount Sinai Hospital at the University of Toronto is serving as ACRIN principal investigator, while Dr. Michael Gold of the University of Oklahoma is the GOG study chair.
By AuntMinnie.com staff writers
October 9, 2007
Related Reading
US breast trial leaders aim to discuss ACRIN 6666 data at RSNA, October 8, 2007
Study of two large screening cohorts favors VC over OC, October 4, 2007
Weed out variability, bias in trial design, October 1, 2007
ACRIN trial shows VC ready for widespread use, September 28, 2007
ACRIN to launch new PET trial, April 3, 2007
Copyright © 2007 AuntMinnie.com
